Fujifilm to invest over $2bn to build large scale US cell culture facility
Tokyo headquartered, Fujifilm Corporation, has announced a new US$2bn (£1.4bn/€1.5bn) investment to establish a new large-scale biopharma site in the US.
The facility will be operated by its subsidiary, Fujifilm Diosynth Biotechnologies, which has locations in Teesside, UK, in North Carolina and Texas in the US and in Hillerød, Denmark.
The move serves to further underline Fujiflim’s ambitions within the contract development and manufacturing (CDMO) space, following its US$928m investment, announced last year, to expand its site in Hillerød, Denmark, and the capital it is ploughing into its UK and US facilities.